Message from Top Management

Aiming to become a specialized pharmaceutical trading company and
a top manufacturer of distinctive generic injectables
forging an entirely new type of pharmaceutical group
At KOA Shoji Holdings Group, we have always embraced challenges in the pharmaceutical industry. Our group is comprised of KOA Shoji, which focuses on active pharmaceutical ingredient (API) sales; KOA Isei and KOA Biotech Bay, which handle pharmaceutical manufacturing and sales; and KOA Shoji Holdings, which oversees these three companies. Together, through our unique business model that integrates trading and manufacturing, we drive innovation and support the pharmaceutical sector.
Last year, we unveiled our growth strategy leading up to 2030, setting a financial target of achieving 8 billion yen in consolidated operating profit. We are fully committed to reaching this goal. We are confident that it is achievable through the stable revenue base of our API sales business, coupled with the continued growth of our pharmaceutical manufacturing and sales operations. A critical component of this growth is the Zao Second Plant, which is scheduled to begin operations in July 2027. The synergy between the Zao Plant, which has been operational since 2017 and specializes in small-lot, multi-product production, and the Zao Second Plant, which focuses on large-scale production, will establish a "Contract Development and Manufacturing Organization (CDMO)" system. This system allows us to provide comprehensive services from drug development to manufacturing. Establishing this CDMO system is a crucial objective for our pharmaceutical manufacturing and sales business and will be the foundation of our continued growth.
Our mission as a group is to contribute to the stable supply of pharmaceuticals. While working toward achieving our goals for 2030, we will continue to take on new challenges as a company that society depends on. We sincerely ask for your continued support and cooperation as we move forward.
(*) API = Active Pharmaceutical Ingredients
(Published on February 2025)
KOA SHOJI HOLDINGS Co., Ltd.
President and Representative Director
Toshiyuki Shuto